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An isotope tags for relative and absolute quantitation (iTRAQ)-based reversed-phase liquid
chromatography (RPLC)-tandem mass spectrometry (MS/MS) method was developed for
differential protein expression profiling in complex cellular extracts. The estrogen positive
MCF-7 cell line, cultured in the presence of 17-estradiol (E2) and tamoxifen (Tam), was used
as a model system. MS analysis was performed with a linear trap quadrupole (LTQ)
instrument operated by using pulsed Q dissociation (PQD) detection. Optimization experi-
ments were conducted to maximize the iTRAQ labeling efficiency and the number of
quantified proteins. MS data filtering criteria were chosen to result in a false positive
identification rate of 4%. The reproducibility of protein identifications was 60%–67%
between duplicate, and 50% among triplicate LC-MS/MS runs, respectively. The run-to-run
reproducibility, in terms of relative standard deviations (RSD) of global mean iTRAQ ratios,
was better than 10%. The quantitation accuracy improved with the number of peptides used
for protein identification. From a total of 530 identified proteins (P  0.001) in the E2/Tam
treated MCF-7 cells, a list of 255 proteins (quantified by at least two peptides) was generated
for differential expression analysis. A method was developed for the selection, normalization,
and statistical evaluation of such datasets. An approximate 2-fold change in protein
expression levels was necessary for a protein to be selected as a biomarker candidate.
According to this data processing strategy, 16 proteins involved in biological processes such
as apoptosis, RNA processing/metabolism, DNA replication/transcription/repair, cell prolif-
eration and metastasis, were found to be up- or down-regulated. (J Am Soc Mass Spectrom
2009, 20, 1287–1302) © 2009 American Society for Mass SpectrometryRecently, two-dimensional liquid chromatogra-phy (2DLC) with tandem MS detection hasemerged as an attractive technology for quanti-
tative proteomic profiling of complex cellular extracts
[1–4]. Stable isotope labeling and label-free quantitation
strategies have been explored [4–13]. Isotope labeling
approaches rely on the covalent attachment of stable
isotope tags to specific amino acid residues of proteins
or peptides during metabolic, enzymatic, or chemical
processes. Label-free quantitation methods rely on mea-
suring peak areas, intensities, or spectral counts, and
benefit from not having to chemically alter the sample.
Throughput, however, is lower, and quantitation errors
are higher, as the samples are processed independently.
Among chemical labeling techniques, isotope tags for
relative and absolute quantitation (iTRAQ) has received
much attention [14–30]. In this approach, peptides are
labeled with isobaric tags at the N-terminus and the
lysine side chains. MS/MS fragmentation produces
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information. Perhaps the most attractive advantage of
this approach is that it can be used for the simultaneous
quantification (relative or absolute) of up to four/eight
different samples. Simplicity, of course, is an added
benefit.
A number of publications have addressed the per-
formance and challenges associated with the iTRAQ
labeling strategy. Using 2D-gel or LC sample fraction-
ation and matrix assisted laser desorption ionization
(MALDI)-time-of-flight (TOF)/TOF detection, Wu et al.
have reported a comparative study of three proteomic
quantitative methods, namely, difference gel electro-
phoresis (DIGE), cleavable isotope coded affinity tag-
ging (cICAT), and iTRAQ [5]. All three methods exhib-
ited relatively good accuracy (experimental protein
ratios for standards were within 81%–122% of the
expected theoretical values), and were found to be
complementary in nature. DeSouza et al. used iTRAQ
and cICAT to identify potential cancer markers in
endometrial tissues [26]. A total of 63 and 68 proteins
were identified and quantified with iTRAQ and cICAT,
respectively, and nine combined putative markers that
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expression level were found. The RSD of differential
expression ratios was in the range of 1%–67%. Cur-
rently, there has been growing interest in developing
proteomic quantitative protocols for a variety of biolog-
ical applications that involve, for example, the study of
protein–protein interactions [16], the monitoring of
temporal changes in perturbed signaling pathways [18],
and the discovery of novel disease biomarkers in sam-
ples of biological origin [27–30]. For example, Kesha-
mouni et al. performed differential protein expression
analysis of lung cancer cells undergoing epithelial-
mesenchymal transition using iTRAQ followed by
2DLC-MS/MS [29]. Out of 325 identified proteins, 29
were found to be up-regulated and 22 down-regulated.
To account for technical errors, replicate experiments
were conducted and data normalization was imperative.
As iTRAQ quantitation is based on detecting and
measuring the intensity of low m/z fragment ions gen-
erated by tandem MS [21], most iTRAQ-LC-MS/MS
based research has been carried out on TOF/TOF-MS
instruments. More recently, a novel approach for pre-
cursor ion activation/dissociation in ion trap mass
spectrometers that allows for the trapping of low m/z
ions, termed pulsed Q dissociation (PQD), has been
developed. Very few studies, however, describe the
performance of the iTRAQ labeling/PQD approach for
quantitative proteomics [31–33]. The main focus of
these studies was on optimizing key PQD parameters
such as collision energy (CE), activation Q, and delay
time (T) to improve the quantitation accuracy and
detection limits. These studies have shown that PQD
operation has a much narrower range of optimal CE
values than CID, and that this range has no universal
settings for all LTQ instruments [32, 33]. Further work
has demonstrated that the quantitation accuracy of
isotope labeled peptides can be much improved if a
high-resolution/high mass accuracy instrument, such
as the Orbitrap, is used for detection (due to the
capability to distinguish between ion species with very
close m/z) [33, 34]. In the present work, we have
developed an iTRAQ-RPLC/MS/MS strategy using
PQD detection on a low-resolution linear ion trap mass
spectrometer, and evaluated the performance of this
approach for the analysis of complex cellular extracts in
terms of reproducibility and accuracy of protein iden-
tifications and quantitation, respectively. This MS sam-
ple processing strategy was complemented by an effec-
tive statistical approach for the selection of putative
biomarker candidates (based on the calculation of four
iTRAQ ratios for each protein), and demonstrated for
the analysis of breast cancer cells.
Experimental
Reagents
MCF-7 breast cancer cells and common cell culturing
reagents (Eagle’s minimum essential medium-EMEM,fetal bovine serum-FBS, insulin, trypsin/EDTA) were
purchased from ATCC (Manassas, VA). Phenol red-free
DMEM (Dulbecco’s modified Eagle’s medium) was
from Invitrogen (Carlsbad, CA), charcoal/dextran
treated fetal calf serum from HyClone (Logan, UT),
and trypsin (phenol red free) from SAFC Biosciences
(Lenexa, KS). -Estradiol (E2), tamoxifen (Tam), L-
glutamine, protease inhibitors (NaF, Na3VO4), buffers
and denaturing reagents (trifluoroacetic acid, acetic
acid, formic acid, TrisHCl, sodium chloride, urea,
dithiothreitol-DTT), and all bovine protein standards
(hemoglobin /, serum albumin, cytochrome c, -
lactalbumin, carbonic anhydrase, -casein, -casein,
and fetuin) were purchased from Sigma (St. Louis, MO).
RIPA lysis buffer was from Upstate (Lake Placid, NY)
and sequencing-grade modified trypsin from Promega
Corp. (Madison, WI). iTRAQ reagents were purchased
from Applied Biosystems (Foster City, CA). Ammo-
nium bicarbonate was from Aldrich (Milwaukee, WI).
HPLC-grade methanol and acetonitrile were obtained
Fisher Scientific (Fair Lawn, NJ). All aqueous solutions
were prepared using D.I. water from a MilliQ Ultrapure
water system (Millipore, Bedford, MA).
MCF-7 Cell Culture
For initial optimization studies, MCF-7 breast cancer
cells were cultured according to a procedure described
in detail elsewhere [35]. Briefly, the cells were grown to
70% confluence in EMEM containing 10% FBS and 10
g/mL bovine insulin (maintenance medium), at 37 °C,
in a humidified atmosphere of 5% CO2. The cells were
rinsed with phosphate buffered saline (PBS, pH 7.4),
and a solution of trypsin/EDTA (0.25% trypsin/0.53
mM EDTA) was added for cell detachment. Following
incubation for 5 to 10 min, culture medium was added
to stop the digestion. The cells were centrifuged/rinsed
with PBS, harvested and stored at 80 °C. For protein
differential expression analysis, MCF-7 breast cancer
cells were first cultured in maintenance medium for
approximately 2 wk (see above). To precondition the
cells before experimental treatment, the medium was
changed to a 3:2 mix of DMEM red-free (complemented
with 10% charcoal stripped fetal calf serum, 1 g/mL
insulin and L-glutamine 4 mM) and EMEM (comple-
mented with 10% FBS and 10 g/mL insulin) for 1 d,
and then to complete DMEM red-free (complemented
with 10% charcoal stripped fetal calf serum, 1 g/mL
insulin and L-glutamine, 4 mM) for 6 d. [Note: Charcoal
treated fetal calf serum has reduced levels of hormones
and growth factors, while red-free DMEM is missing
the phenol-red pH indicator, which is an estradiol
mimic. By eliminating the influence of other growth
hormones or estradiol mimics, the effect of estradiol
stimulation can be more accurately evaluated]. Next,
DMEM red-free cultured cells, at 35%–40% conflu-
ence, were divided into four batches and further stim-
ulated with (A) E2 (1 nM), (B) E2 (1 nM)/Tam(1 M),
(C) E2 (10 pM)/Tam (1 M), and (D) Tam (1 M). Cells
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stored at 80 °C. The confluence level for the four
culturing conditions before harvesting was 70%–80%
for condition A, 65%–75% for condition B, and
45%–55% for conditions C and D, demonstrating
that in the presence of very low E2 concentrations
(i.e., 10 pM), or complete absence of E2, tamoxifen
suppresses the proliferation of MCF-7 breast cancer
cells. For differential protein expression studies, the
same amount of protein extract from each cell state
was used for analysis.
Cell Lysis and Protein Extract Processing
Cells were thawed and lysed following a procedure
described in previous work [35]. The cell lysis solution
was prepared from 1 mL RIPA buffer (500 mM TrisHCl
pH 7.4, 1.5 M NaCl, 10% NP-40, 2.5% deoxycholic acid,
10 mM EDTA), 100 L protease inhibitor cocktail (104
mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM
bestatin, 1.5 mM pepstatin A, 1.4 mM E-64), 100 L NaF
(100 mM) and 50 L Na3VO4 (200 mM) as phospha-
tase inhibitors, and 8.75 mL of ice cold water. Cell and
lysis buffer were mixed in a ratio of 1:10, incubated/
rocked for 2–3 h at 4 °C, and centrifuged for 15 min
at 13,000 rpm at 4 °C. The protein content in the
supernatant was measured at 595 nm (Bradford assay)
using a SmartSpec Plus Spectrophotometer (Bio-Rad,
Hercules, CA), and the samples were stored at 80 °C.
For further processing, the samples were thawed, the
soluble protein extract was treated with urea (8 M) and
DTT (4.5 mM) for 1 h at 60 °C, diluted 10 with 50 mM
NH4HCO3, and digested with trypsin (24 h) at 37 °C
(substrate:enzyme ratio was 50:1). The protein digest
solution was cleaned up from salts and buffer compo-
nents with SPEC-PTC18 solid-phase extraction pipette
tips (Varian Inc., Lake Forest, CA). Insulin treated
MCF-7 cell extracts were spiked after tryptic digestion
with a 9-protein mix digest solution, before SPEC-
PTC18 clean-up and iTRAQ labeling. E2 and Tam
treated MCF-7 cell extracts were spiked with a 5 M
solution of 8 standard bovine proteins before tryptic
digestion (to result in a final concentration, after diges-
tion, of 100 g/mL in protein extract and of 0.05 M
in standard proteins).
iTRAQ Labeling
A protocol for iTRAQ labeling was developed and
evaluated by using standard proteins (hemoglobin /,
bovine serum albumin, cytochrome c, -lactalbumin,
-casein, -casein, albumin, and fetuin) and MCF-7 cells
cultured in maintenance medium. The method was
subsequently applied to protein differential expression
analysis of MCF-7 cells cultured in the presence of E2
and Tam. MCF-7 protein extract tryptic digest solutions
(4–125 g protein content), each processed separately
with a SPEC-PTC18 cartridge, were concentrated to
5–10 L with an Eppendorf Vacuufuge (EppendorfAG, Hamburg, Germany), re-dissolved in 25-30 L
iTRAQ dissolution buffer (provided in the iTRAQ kit),
and treated each with iTRAQ reagent solution for 2 h at
room temperature (the iTRAQ reagents being each
dissolved in 70 L of ethanol). The labeled samples
were combined in various ratios, cleaned up with
SPEC-PTSCX solid-phase extraction pipette tips (Varian
Inc.) to eliminate compounds that may interfere with
MS analysis, brought to dryness, and ultimately re-
dissolved in LC buffer system A. For optimization
studies, four aliquots (72 g protein content each) of an
MCF-7 (EMEM/insulin culture) protein extract digest
solution, spiked with standards after digestion but
before SPEC-PTC18 clean-up (see above), were la-
beled with iTRAQ reagents 114, 115, 116, and 117,
and mixed in a ratio of 0.2:1:1:5. Alternatively, differ-
ent amounts (4, 20, 20, and 100 g) of the same cell
extract were labeled with iTRAQ reagents and mixed
in a ratio of 1:1:1:1, to generate the same final protein
ratios of 0.2:1:1:5. In addition, three aliquots (5, 25, and
127 g) of a standard protein mix digest solution (0.5
M) were labeled with iTRAQ reagents 114, 116, and
117, and combined 1:1:1 to generate protein ratios of
0.2:1:5. E2 and Tam treated samples (80–100 g each),
spiked with standards before digestion (see above),
were labeled with iTRAQ reagents and mixed in A:B:
C:D ratios of 1:1:1:1 (4-plex experiment), or in A:A:C:C
ratios of 1:1:1:1 (double 2-plex experiment). One 4-plex
and one double 2-plex experiment were conducted for
optimization work, and a second double 2-plex experi-
ment was conducted for the final differential protein
expression study.
RPLC-ESI-MS/MS
RPLC-MS/MS analysis was performed using a micro
liquid chromatography system (Agilent Technologies,
Palo Alto, CA) and an LTQ ion trap mass spectrometer
(Thermo Electron Corp., San Jose, CA). Coupling of the
LC system to the LTQ was accomplished via an
on-column/no-split injection set up described in detail
elsewhere [35]. The separation column was a 100 m
i.d.  12 cm capillary packed with 5 m Zorbax SB-C18
particles (Agilent Technologies). A nanospray emitter
was generated by inserting a 1 cm long (20 m i.d. 
90 m o.d.) capillary into the separation column. Mo-
bile phase A was H2O:CH3CN (95:5 vol/vol) and mo-
bile phase B was H2O:CH3CN (20:80 vol/vol), each
containing 0.01% CF3COOH. The volumetric flow rate
in the separation column was set to 160–180 nL/min,
with a 3 h long separation gradient running from 0% to
100% B.
MS data were acquired using data-dependent acqui-
sition conditions: each MS event was followed by
zoom/MS2 scans on the five top-most intense peaks;
zoom scan width was 5 m/z; dynamic exclusion was
enabled at repeat count 1, repeat duration 30 s, exclu-
sion list size 200, exclusion duration 60 s, and exclusion
mass width  1.5 m/z; PQD parameters were set at
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activation Q 0.7, and activation time (T) 0.1 ms; the
threshold for MS/MS acquisition was set to 100 counts.
Protein identification was performed with the Bioworks
3.3 software (Thermo Electron Corp., San Jose, CA)
using a minimally redundant human protein database
downloaded from the ExPASy/SwissProt website on
January 22, 2007 (37,690 entries, including 12 bovine
proteins that were used for spiking the sample) [36].
The database search parameters included the follow-
ings settings: number of allowed missed tryptic cleav-
age sites was set to 2, the peptide tolerance was 2 u, the
fragment ion tolerance was 1 u, and only fully tryptic
fragments were considered for peptide selection. Five
iTRAQ related dynamic modifications (144.1 Da) at
the N terminus and at four additional lysine residues
were allowed, and all peptides were assigned to unique
protein references. Peptides that carried additional
amino acid modifications were observed in our study
(13% of all internal tyrosines were found to be labeled
with iTRAQ reagents, and 4% of all lysines were
carbamylated), however, these peptides typically dis-
played low quality tandem mass spectra. To avoid false
positive peptide identifications and a distortion of pro-
tein iTRAQ ratios, such modifications were not allowed
in the final quantitation analysis. The sensitivity thresh-
old and mass tolerance for extracting the iTRAQ ratios
were set to 1 and0.5, respectively (Note: the Bioworks
software, to the authors’ best knowledge, does not
correct for isotope overlap between iTRAQ reporter
ions). Data filtering parameters were chosen to generate
false positive protein identification rates of4%, as calcu-
lated by searching the MS2 scans against a forward-
reversed database of proteins (compiled from the orig-
inal SwissProt database). At the peptide level, mass
spectral filtering was accomplished with the Xcorr
versus charge state parameter set at minimum 1.5, 2.0,
and 3.0 for singly, doubly, and triply charged peptides,
respectively. Specific settings for various experiments
are described at appropriate locations in the text. At the
protein level, only top matching proteins with P 0.001
were considered for analysis. The P value represents the
probability of a random match for a peptide, as gener-
ated by the Bioworks software from the parameters that
characterize the quality of a tandem mass spectrum. For
proteins identified by a single peptide, the P value of
the protein has the same value as the P value of the
matching peptide. For proteins matched by several
peptides, the P value is adjusted to reflect increased
confidence in the identification of that protein.
Results and Discussions
Breast cancer cell lines are commonly used as model
systems to investigate the pathways that lead to the
development of cancer [37–45]. In a previous work, we
generated a full proteome profile of the MCF-7 cell line
using 2DLC-MS/MS technology [35]. The study re-
sulted in the identification of 2000 proteins (P 0.001), of which 200 were correlated with cellular pro-
cesses relevant to cancer. The objective of the present
study was to develop and assess the effectiveness of a
one-step iTRAQ-LC-MS/MS approach, using ion-trap
PQD technology, for protein differential expression
analysis in complex cellular extracts. A systematic eval-
uation of iTRAQ labeling efficiency, PQD parameter
settings, reproducibility of protein identifications by
LC-MS/MS, and reproducibility and accuracy of iTRAQ
quantitation, was performed. The identification and
quantitation of a large number of proteins, as facilitated
by the analysis of cellular extracts, has enabled the
implementation of a global normalization process and
of a statistical approach for selecting differentially ex-
pressed proteins.
iTRAQ Labeling Reaction Efficiency
The iTRAQ reagents are isobaric components used
for tagging peptides for MS quantitation. They con-
sist of a reporter group (N-methylpiperazine derived),
a balance group (carbonyl), and a reactive group (N-
hydroxysuccinimide ester) that links to peptides via the
N-terminus and the lysine side chains [21]. To improve
detection limits and quantitation accuracy, all peptides
should be fully labeled. Because other sample compo-
nents having primary amino groups in their structure
may interfere with the labeling reaction, proper sample
preparation is imperative for the success of the tech-
nique. Of specific concern for our experiments were the
typical Tris and ammonium bicarbonate buffers that
were used during cell extract preparation. The labeling
efficiency was investigated with standard mixtures of
proteins and MCF-7 extracts that enabled the counting
of 400 and 2000–4000 peptide hits, respectively.
Samples containing 50–100 g protein were labeled
with iTRAQ reagent 114, and processed as described in
the experimental section. The percentage of all N-
terminal amino acids, internal lysines and C-terminal
lysines that were chemically modified with the 144.1
m/z iTRAQ tag, out of all eligible peptide hits, was
determined. To achieve a 90% labeling efficiency, the
samples were cleaned-up before iTRAQ labeling with
SPEC-PTC18 cartridges to remove the amine-containing
buffers, and the labeling reaction was allowed to pro-
ceed for 2 h, instead of 1 h, as suggested by the
manufacturer. Without effective sample clean-up mea-
sures the labeling efficiency was significantly compro-
mised, affecting especially the N-terminal residues
where the percentage of labeled amino acids dropped to
50%. By using optimized conditions for sample pro-
cessing, the experiment that involved the analysis of
E2/Tam treated MCF-7 cells resulted in the labeling of
93% of all lysines and N-terminal amino acids. Spe-
cifically, we found that only 2.4% of C-terminal ly-
sines (out of 2365), 6.7% of internal lysines (out of
2840), and 2% of N-terminal lysines (out of 100), as
well as 7.3% of all N-terminal amino acids (out of
4304), were not labeled with iTRAQ reagents. A total of
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that: all peptide hits matched proteins with P  0.001,
but not all peptide hits had P  0.001, per se; peptides
were filtered with the Xcorr versus charge state param-
eter set at 1.5, 2.0, and 3.0; and the peptide level false
positive rate was 1.6–2%, i.e., below the 7%–10% of
nonlabeled peptides.
PQD Operation
The PQD method in an LTQ-MS instrument relies on
activating the precursor ions at high Q values for a very
short time (T), and then performing ion fragmentation/
daughter ion collection at low Q values to enable the
trapping of low m/z ions. As relatively few results have
been reported so far with this novel ion dissociation
method, the Q and T parameters, and the collision
energy, were varied in an attempt to maximize the ion
fragmentation/trapping efficiency, and, therefore, in-
crease the number of identified/quantified proteins (see
PQD optimization in Supplementary material, which
can be found in the electronic version of this article). As
the Q  0.7, T  0.1 ms, and CE  35% conditions
generated some of the largest number of identified
proteins (P  0.001), all future experiments were per-
formed using these parameter settings. Overall, how-
ever, PQD detection enabled the identification of only
50%–65% of proteins that were detected with conven-
tional CID. This outcome was a result of less efficient
peptide fragmentation in the PQD operation mode of
the ion trap (many tandem mass spectra being domi-
nated by the undissociated parent ion). In this study,
best PQD performance was observed at CE settings of
31%–35%, close to the typical values that are used for
CID. Over time, however, changes in the optimal CE
values have been observed, thus, CE optimization be-
fore performing a new set of experiments was neces-
sary. Nevertheless, a strong and recurring distortion
of iTRAQ reporter ion intensities with increased
collision energy settings was not observed (i.e., con-
sistently lower intensity m/z 114 versus m/z 117 [32]).
The values of the global iTRAQ ratios confirmed the
lack of a consistent bias in the detection of 114 –117
Table 1. Identification/quantitation of MCF-7 proteins, and run
Conditions: MCF-7 cells were cultured in EMEM/insulin, labeled
0.2:1:1:5. iTRAQ ion 116 was used as a reference. The protein con
1 g/L. LC injection volumes were 8 L. Proteins that were c
peptides that passed the Xcorr versus charge state filter (1.9, 2.2,
runs.
Run #
# Detected
proteins
0.2:1
# Quantified
proteins (%)
Global
iTRAQ rati
Run 1 272 199 (73%) 0.37
Run 2 305 222 (73%) 0.38
Run 3 296 214 (72%) 0.35
Multiconsensus 472 389 (82%) 0.36reporter ions. Detailed explanations on how the
global iTRAQ was calculated are provided in the
following sections.
Reproducibility of Protein Identifications
Before conducting quantitative analysis of unknown
samples, a qualitative evaluation of the iTRAQ-LC-
MS/MS protocol, in terms of number of identified
proteins, percent of false positives, and reproducibility
of protein identifications, was carried out. For this
purpose, MCF-7 cell extracts (72 g protein content in
each batch) were labeled with iTRAQ reagents 114, 115,
116, and 117, and mixed in a ratio of 0.2:1:1:5 (i.e., 3
g:15 g:15 g:72 g) to cover a dynamic range of 25
(see the Experimental section). Batch number three was
labeled with reagent 116, and was used as a reference
for quantitation. Further discussions in the text will
analyze the outcome of this experiment as a whole, or in
terms of mixing ratios 0.2:1, 1:1, or 5:1 alone. Depending
on the amount injected on the LC nano-column, the
MS/MS analysis of labeled MCF-7 extracts resulted,
typically, in the identification of 100–500 proteins.
Three consecutive injections of a sample containing 8
g protein extract (according to the initial protein
concentrations measured with the Bradford assay, and
ignoring possible losses during sample processing) re-
sulted in the identification of 272–305 proteins per
LC-MS/MS run. The combined results of all three runs
summed up to 472 proteins, and will be referred from
now on as “multiconsensus” results, as defined by the
Bioworks software (Table 1). These proteins were
matched by a total of 2378 peptides (MS2 scans), of
which 1179 were unique. Only proteins with P  0.001
that were matched by peptides with Xcorr versus
charge state values of 1.9, 2.2, and 3.8 for z  1, 2, and
3, respectively, were considered for comparison. Using
such conditions, with either PQD or CID, the typical
protein overlap between two consecutive runs was
60%–67%, and between three runs 50% (Figure 1).
Such low overlap between protein I.D.s relates to the
low abundant proteins that generate very few and low
intensity peptides. As a result of small changes in
n reproducibility of global iTRAQ ratio measurements.
iTRAQ reagents 114, 115, 116, and 117, and mixed in a ratio of
ation in the final sample subjected to LC-MS/MS analysis was
ed as detected/quantified had P  0.001, and were matched by
Multiconsensus results were generated from three LC-MS/MS
Theoretical iTRAQ ratios
1:1 5:1
# Quantified
proteins (%)
Global
iTRAQ ratio
# Quantified
proteins (%)
Global
iTRAQ ratio
230 (85%) 1.03 223 (86%) 4.57
254 (83%) 1.16 256 (84%) 5.16
249 (84%) 1.01 250 (84%) 4.45-to-ru
with
centr
ount
3.8).
o421 (89%) 1.04 424 (90%) 4.65
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ent background ions during chromatographic analysis,
and may, or may not be selected for fragmentation
during data dependent MS (typical intra-column repro-
ducibility of retention times was 2%). Thus, the num-
ber of identified proteins can change from one chro-
matographic run to another (typical variations were
5%–10%). We have shown, however, that if the
stringency of the data filtering parameters is high,
and if only proteins that are matched by 2 unique
peptides are considered for comparison, the repro-
ducibility between consecutive runs can be as high as
90%–98% [35].
Reproducibility of iTRAQ Quantitation
The quantitation reproducibility was evaluated in terms
of number of proteins that were quantified in replicate
149
33
64
44
26
305 7779
272
R1 + R2 + R3 = 472
296
Figure 1. Reproducibility of protein identifications across repli-
cate LC-MS/MS runs. Conditions: MCF-7 cells were cultured in
EMEM/insulin, labeled with iTRAQ reagents 114, 115, 116, and
117, and mixed in a ratio of 0.2:1:1:5. The protein concentration in
the final sample subjected to LC-MS/MS analysis was 1 g/L.
LC injection volumes were 8 L. Only proteins with P  0.001,
and that were matched by peptides that passed the Xcorr versus
charge state filter (1.9, 2.2, 3.8), were considered in the analysis.
Total unique proteins identified in all three runs (R1, R2, R3) was
472.
Table 2. Identification and quantitation of proteins in the MCF-
protein identification. Conditions: MCF-7 cells were cultured in E
and mixed in a ratio of 0.2:1:1:5. The protein concentration in the
injection volumes were 8 L. Proteins that were counted as detec
passed the Xcorr versus charge state filter (1.9, 2.2, 3.8). Results w
LC-MS/MS runs.
# Unique peptides/protein # Detected proteins
1 peptide 472
2 peptides 268
3 peptides 169
4 peptides 127
5 peptides 95LC-MS/MS runs, and of individual or global RSD
values of iTRAQ ratios. Certain peptides that generated
good quality tandem mass spectra for identification
purposes did not produce iTRAQ reporter ions in the
low m/z region of the mass spectrum, presumably
because the PQD fragmentation was not efficient. Al-
ternatively, the intensity of the reporter ions in the mass
spectrum was very low. As a result, these peptides and
the corresponding proteins (if matched by such pep-
tides only) could not be quantified. We note that the
protein iTRAQ ratios were calculated as an average of
all contributing peptide iTRAQ measurements. For the
example provided in the previous section, the run-to-
run variability, in terms of quantified proteins in three
consecutive LC-MS/MS analyses, is also summarized in
Table 1. For any single analysis, the number of quanti-
fied proteins represented 72%–86% of the identified
proteins, while for the multiconsensus results, this
number increased to 82%–90%. The injection of 8 g
sample (0.22 g:1.1 g:1.1 g:5.5 g) enabled the
quantitation of 199–222, 230–254, and 223–256 pro-
teins for sample ratios 0.2:1, 1:1, and 5:1, respectively.
An advantage of performing repetitive LC-MS/MS
analyses is that complementary information can be
obtained from several injections, thereby, increasing not
only the total number of identified or quantified pro-
teins, but also the protein sequence coverage and quan-
titation accuracy. The effect of protein sequence cover-
age, i.e., of the number of unique peptides/protein, on
protein identification and quantitation, is shown in
Table 2 (generated with the same MS/MS data that
were used for generating Table 1). As expected, the
more peptide matches required for a protein I.D., the
smaller the subset of proteins that could be identified.
The percentage of quantified proteins (out of total
identified) increased, however, from 82%–90% to 99%–
100%, as the number of matching peptides per protein
was increased from one to five, respectively. Most
importantly, for quantitation purposes, 94% of the pro-
teins that were identified by at least two peptides (as
typically required for confident protein identification)
generated measurable iTRAQ ratios for quantitation.
The RSD of iTRAQ ratios for individual protein
standards spiked into the MCF-7 extracts was in the
range of 5%–50% (across three repetitive runs). This
line as a function of the number of unique peptides used for
/insulin, labeled with iTRAQ reagents 114, 115, 116, and 117,
sample subjected to LC-MS/MS analysis was 1 g/L. LC
quantified had P  0.001, and were matched by peptides that
enerated from a multiconsensus file prepared from three
Q ratio 0.2:1 iTRAQ ratio 1:1 iTRAQ ratio 5:1
# Quantified proteins (%)
389 (82%) 421 (89%) 424 (90%)
251 (94%) 262 (98%) 263 (98%)
166 (98%) 169 (100%) 169 (100%)
125 (98%) 127 (100%) 127 (100%)7 cell
MEM
final
ted/
ere g
iTRA94 (99%) 95 (100%) 95 (100%)
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ance associated with the measurement of iTRAQ ratios
for individual peptides. While it was beyond the pur-
pose of this study to develop a statistical method that
would incorporate the contribution of peptide variance
into the protein-level variance, and into the accuracy of
iTRAQ quantitation, it is worth mentioning the com-
plexity of the problem. The possible individual contrib-
utors to the iTRAQ ratio variance of a protein are: the
number of unique matching peptides, the various
charge states of the same peptide, the number of
tandem mass spectra per unique peptide and per
charge state, the number of iTRAQ tags per peptide, the
number of LC-MS/MS replicates that are performed to
generate multiconsensus results, and the intensity of the
signal. Overall, in this study, variations as high as
300%–500% were occasionally encountered for repeti-
tive measurements of a peptide iTRAQ ratio, and the
variations were generally higher for low intensity sig-
nals (the results are, however, in agreement with the
coefficients of variation reported for PQD detection and
for label-based quantitative methods [25, 30–32, 46–
48]). For example, cytokeratin 18 from one of the MCF-7
extracts was matched by a total of 190 tandem mass
spectra (34 unique peptides), of which 105 generated
measurable iTRAQ ratios. The RSD of all contributing
peptide iTRAQ ratios was as high as 146%. For the case
of only one cytokeratin peptide (V*K*LEAEIATYRR,
“*” indicating the iTRAQ tag) that was observed as a
doubly and triply charged ion, and that was matched
by 36 tandem mass spectra of which 18 generated
measurable iTRAQ ratios, the RSD was smaller, i.e.,
55%. While the variance across all peptides was, obvi-
ously, larger than for a single peptide, a larger number
of total measurements for any given protein resulted in
a more reproducible (and ultimately more accurate)
protein iTRAQ ratio. We note that the variation in
peptide iTRAQ ratios was not introduced by sequence
redundancy between different keratins (i.e., peptide
contributions from various keratins with different
abundance), but rather by random differences between
iTRAQ ratios generated for the same peptide by differ-
ent tandem mass spectra. Only one of the keratin 18
matching peptides (IVLQIDNAR) was also identified
in keratin 19, however, the contribution of this pep-
tide to the iTRAQ variance was minimal (1 out of 105
measurements). Low m/z contaminants that could
overlap with the iTRAQ reporter ions are not observ-
able on a low-resolution ion trap mass spectrometer,
thus, it was not possible to assess whether such
interferences affected the outcome of these experi-
ments or not.
Due to the relatively broad range of individual
protein RSD values, to gain a better understanding of
how well an experiment evolved, we introduced the
calculation of a “global iTRAQ ratio”, defined as the
average of all protein iTRAQ ratios within a given
dataset that passed certain data filtering criteria (for
example, Xcorr versus charge state and P-threshold).We hypothesized that this global iTRAQ could provide
a better measure for a preliminary assessment of overall
quantitation reproducibility. As the calculation of the
global iTRAQ involved averaging iTRAQ ratios for
hundreds of proteins, the global RSDs were indeed
much smaller than that of individual proteins, i.e.,
4%–8% (as calculated from the three replicate analy-
ses shown in Table 1). Experiments performed months
later on the same sample demonstrated similar consis-
tency in the values of the global iTRAQ, and confirmed
its utility for evaluating not only global quantitation
reproducibility but also accuracy.
Accuracy of iTRAQ Quantitation
Relative quantitation of proteins in cellular extracts
relies on the following assumptions: (1) the total
amount of protein extract considered for analysis is the
same for each cell state, (2) the expression level of most
proteins does not change in response to the perturba-
tion considered in the study, and (3) the change in
expression level of some proteins, if any, as a result of
the perturbation, will have a negligible impact on the
overall quantitation/normalization protocols. As a re-
sult of these assumptions, we speculated that (1) the
value of the experimentally determined global iTRAQ
ratios should be close to the theoretical values, i.e., to
the mixing ratios of the proteins from each cell state, (2)
any major departure of the experimental global values
from the theoretical values should be the result of a
global bias that could be corrected by a normalization
process, and (3) the global iTRAQ ratios could be used
for (global) data normalization, such use being sup-
ported by the reproducibility of data shown in Table 1.
Major contributors to a global bias could be factors
related to: (a) sample processing steps (for example,
inaccurate protein concentration measurements, non-
uniform recovery of entire extracts from C18 clean-up
cartridges, loss of sample during precipitation/re-
dissolution, etc.); (b) data processing artifacts (for ex-
ample, it was observed that the iTRAQ values were
somewhat dependent on the threshold setting parame-
ter that was used by Bioworks for their calculation);
(c) dependence of iTRAQ reporter ion intensities on
collision energy (as reported by Griffin et al. [32], even
though in our data we did not observe such an effect);
and, (d) isotope contamination between iTRAQ re-
agents (consistent contamination, however, was not
observed in this work). To correct for this bias, individ-
ual protein iTRAQ values were calculated by normal-
izing the experimental data with the aid of correction
factors, according to the following equations:
iTRAQPRON iTRAQPRO ⁄ CF (1)CF iTRAQG ⁄ iTRAQTHEOR (2)
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where iTRAQPRON is the normalized iTRAQ ratio of a
protein, iTRAQPRO is the experimentally determined
iTRAQ ratio of a protein (i.e., the average iTRAQ ratio
of all corresponding peptides), iTRAQG is the global
iTRAQ ratio (i.e., the average of all protein iTRAQ
ratios within a given dataset), iTRAQTHEOR is the theo-
retical iTRAQ ratio (i.e., the mixing ratio), CF is the
correction factor (for theoretical mixing ratios of 1:1:1:1,
the correction factor is equal to the global iTRAQ), and
n is the number of proteins in the dataset.
Table 3 displays global iTRAQ ratios for various
datasets, and the corresponding correction factors that
were generated for normalization purposes. Data are
provided for six independent iTRAQ experiments in-
volving the labeling of different sample amounts and
mixing of samples in different ratios, as well as different
cell culturing conditions: one standard protein mixture,
two sets of MCF-7 cells cultured in the presence of
insulin, and three sets of MCF-7 cells cultured in the
presence of E2/Tam. Three to five LC-MS/MS injec-
tions were performed for each experiment to generate
multiconsensus results. Rows 6 and 7 in Table 3 refer to
the same iTRAQ experiment, but involve different data
filtering parameters. Most global correction factors had
values in the range of 0.5–2.2, with a few extremes in
the range of 0.3–4. The cell states that were used as a
reference for quantitation were assigned an iTRAQ ratio
of 1. Generally, the errors were higher for the lower end
of the quantitation scale, with the least sample consid-
ered for analysis (note one case of a correction factor of
3.95 for one of the smallest batches of labeled standard
proteins). The effect of the global normalization pro-
cess on individual iTRAQ ratios for standard proteins
spiked into MCF-7 extracts is shown in Table 4.
Results are shown for three independent iTRAQ
experiments involving cell extracts 3, 4, and 6 from
Table 3, using unique or different cell culturing
conditions. For insulin-only cultured cells, and iTRAQ
Table 3. Global iTRAQ ratios and corresponding correction fact
Sample
Amounts
labeled (g)
Injection
amount/
volume #
1. Standard 9 mixa 5:25:127 4 g/8 L
2. MCF-7/insulina 72:72:72:72 8 g/8 L
3. MCF-7/insulina 4:20:20:100 3 g/8 L
4. MCF-7/E2/Tam/4plexa 100:100:100:100e 40 L
5. MCF-7/E2/Tam/2plexb 80:80:80:80e 40 L
6. MCF-7/E2/Tam/2plexa 100:100:100:100 16 g/8 L
7. MCF-7/E2/Tam/2plexb 100:100:100:100 16 g/8 L
aPeptides were filtered with the Xcorr versus charge state filter set at 1
bPeptides were filtered with the Xcorr versus charge state filter set at 1.
iTRAQ measurements were counted (see additional selection criteria in
cThe reference ions have an iTRAQ value of 1.
dIn this experiment, iTRAQ labels 116, 114, and 117 were used for labe
eVery little sample was available for analysis, and part of the sample
known, and a much smaller number of proteins were identified/quantified.
# Inj. stands for LC-MS/MS injections.mixing ratios of 0.2:1:1:5 (Table 4/column 2), the nor-
malized experimental measurements were in the range
of (0.14–0.3):(0.82–1.60):1:(2.92,–6.25). For cells cultured
using two different conditions, in the presence of E2
and Tam, and iTRAQ mixing ratios of 1:1:1:1 (Table
4/columns 3 and 4), the normalized measurements were
in the range of (0.48–2.68). The quantitation errors
seemed to be somewhat higher when additional biases
were introduced by culturing and processing the cells
independently, processes that involved separate cell
harvesting, lysing, protein concentration measurement
through the Bradford assay and tryptic digestion (note
a range of 0.48–2.68 for E2/Tam cultures versus a range
of 0.82–1.60 for insulin cultures at 1:1 mixing ratios).
This observation was evident from the global correction
factors, as well, shown in Table 3 (column 8): for
E2/Tam cultures the global correction factors were in
the range of 0.31–3.03, while for the insulin cultures in
the range of 0.84–1.8. Overall, at the individual protein
level, the global normalization process reduced the
quantitation errors to less than 2- to 3-fold.
Once a global average (iTRAQG) was determined
for an LC-MS/MS experiment, the percent variation
for each individual protein was calculated according
to eq 4:
% Variation
 [(iTRAQPRO iTRAQG) ⁄ iTRAQG]  100 (4)
For the previously described LC-MS/MS experiment,
with iTRAQ mixing ratios of 0.2:1:1:5, the distribution
of the iTRAQ % variations for all quantified MCF-7
proteins is shown in Figure 2. Overall, combined data-
sets provided better results than any individual set.
Specifically, for a mixing ratio of 1:1, the multiconsen-
sus results revealed that 60% of proteins could be
quantified with  (0%–30%) accuracy (Figure 2a). In
addition, for mixing ratios that involved larger amounts
of proteins and generated more intense signals, the
quantitation was more accurate, i.e., a larger percentage
easured for various samples and experimental conditions.
# Proteins
(P  0.001)
Mixing
ratios
Global iTRAQ
ratiosc
114:115:116:117
Correction
factors
9 0.2:1:5 0.79:1:6.27d 3.95:1:1.25
472 0.2:1:1:5 0.36:1.04:1:4.65 1.80:1.04:1:0.93
468 0.2:1:1:5 0.32:0.87:1:4.20 1.60:0.87:1:0.84
145 1:1:1:1 1:0.82:0.54:0.31 1:0.82:0.54:0.31
154 (1:1):(1:1) 1:1.61:3.03:2.21 1:1.61:3.03:2.21
407 (1:1):(1:1) 1:2.23:1.88:1.44 1:2.23:1.88:1.44
255 (1:1):(1:1) 1:2.14:1.84:1.43 1:2.14:1.84:1.43
2, and 3.8, and all proteins with P  0.001 were counted.
and 3.0, and only proteins with P  0.001 and matched by two peptide
text).
5, 25, and 127 g protein, respectively (label 114 was the reference).
ost during precipitation; as a result, the exact injection amount is notors m
Inj.
2
3
3
3
3
5
5
.9, 2.
5, 2.0,
the
ling
was l
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Figure 2b, 0.2:1 versus 1:1 and 5:1 ratios). Similar trends
were obtained for the standard proteins that were
spiked into the MCF-7 extract. However, as the accu-
racy of the analytical method is sensitive to the com-
plexity of the sample [5], the analysis of standards
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Run1 (230/272 quantified, global iTRAQ=1.03)
Run2 (254/305 quantified, global iTRAQ=1.16)
Run3 (249/296 quantified, global iTRAQ=1.01)
Multiconsensus (421/472 quantified, global iTRAQ=1.04)
(a)
(b)
Figure 2. Distribution of experimental iTRAQ values for quan-
tified proteins in the MCF-7 cell extract. Conditions were the same
as provided in Table 1. (a) % Variations for individual LC-MS/MS
runs and multiconsensus results are provided for the 1:1 protein
mixing ratio. (b) % Variations for multiconsensus results are
Table 4. Normalized iTRAQ ratios for standard proteins spiked
in the presence of insulin (10 g/mL), or E2/Tam, using the follo
(10 pM)/Tam (1 M), and (D) Tam (1 M). For the insulin stimu
iTRAQ reagents 114, 115, 116, and 117, and mixed in a ratio of 0.
and D were labeled with reagents 114, 115, 116, and 117, respecti
2-plex experiment, cell condition A was labeled with reagents 11
and the samples were mixed in a ratio (A:A):(C:C) of (1:1):(1:1). P
1.9, 2.2, and 3.8, and all proteins with P  0.001 were counted in
Standard proteins
MCF-7/insulin (0.2:1:1:5) M
1.60:0.87:1:0.84
Hemoglobin  0.30:0.93:1:5.17
Hemoglobin  0.24:0.90:1:4.76
-2-HS-glycoprotein 0.26:1.60:1:6.25
-S1-casein 0.26:1.10:1:5.02
-S2-casein 0.15:0.92:1:4.48
-Casein 0.24:0.89:1:2.92
Carbonic anhydrase 0.24:1.21:1:4.99
Cytochrome c 0.22:1.02:1:4.77
-Lactalbumin 0.14:0.82:1:4.04
BSA 0.28:0.98:1:4.85provided for 0.2:1, 1:1, and 5:1 protein mixing ratios.alone, for example at 5:1 mixing ratios, resulted in the
quantification of all proteins within 30% accuracy of
their theoretical ratios.
The % variation of iTRAQ values (1:1 mixing ratio)
as a function of the number of unique peptides that
matched any given protein is shown in Figure 3. Evi-
dently, the accuracy of the method increased with the
number of peptides that were required to identify/
quantify a given protein. The percentage of proteins
that was quantified with (0%–30%) accuracy, in-
creased from 60% to 85%, as the number of unique
peptides/protein was increased from 1 to 5. The num-
ber of quantifiable proteins dropped significantly, how-
ever, if such stringent conditions were used (see also
Table 2). The standard deviations (SD) of iTRAQ ratio
distributions for proteins measured by 1 to 5 peptides
were 0.47, 0.38, 0.30, 0.27, and 0.23, respectively, (we
MCF-7 cell extracts. Conditions: MCF-7 cells were grown either
conditions: (A) E2 (1 nM), (B) E2 (1 nM)/Tam (1 M), (C) E2
cells, different aliquots of the same cell state were labeled with
5. For the E2/Tam 4-plex experiment, cell conditions A, B, C,
and mixed in a ratio A:B:C:D of 1:1:1:1. For the E2/Tam double
115, cell condition C was labeled with reagents 116 and 117,
es were filtered with the Xcorr versus charge state filter set at
nalysis.
/E2/Tam-4plex (1:1:1:1) MCF-7/E2/Tam-2plex (1:1):(1:1)
Correction factors
1:0.82:0.54:0.31 1:2.23:1.88:1.44
ormalized iTRAQ ratios
1:1.84:1.56:2.29 1:1.33:1.58:1.74
1:1.20:1.22:1.35 1:1.04:1.06:1.15
1:1.11:1.15:1.26 1:1.16:2.11:2.16
1:0.93:0.96:0.77 1:1.15:1.48:1.37
1:0.80:1.44:0.68 1:0.85:0.94:1.19
1:1.34:1.57:1.29 1:0.52:1.06:1.27
1:1.12:1:00:1.45 1:0.92:1.16:0.87
1:2.02:1.46:2.68 1:0.84:1.03:1.17
1:0.78:1.07:0.48 1:1.4:0.72:0.61
N/A N/A
iTRAQ Theoretical ratio (1:1)
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1 peptide (421/472 quantified, global iTRAQ=1.04)
2 peptides (262/268 quantified, global iTRAQ=1.01)
3 peptides (169/169 quantified, global iTRAQ=1.02)
4 peptides (127/127 quantified, global iTRAQ=1.05)
5 peptides (95/95 quantified, global iTRAQ=1.02)
Figure 3. Distribution of experimental iTRAQ values for quan-
tified proteins in the MCF-7 cell extract as a function of unique
peptides/protein (1:1 mixing ratio). Conditions were the same as
provided in Table 1. Multiconsensus data from triplicate LC-into
wing
lated
2:1:1:
vely,
4 and
eptid
the a
CF-7
NMS/MS runs were used in the analysis.
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metrical around the mean). These observations empha-
size once again the importance of making a sufficient
number of iTRAQ measurements for every single pro-
tein to obtain reproducible and accurate quantitative
results.
Protein Differential Expression Analysis
In an attempt to verify the applicability of these find-
ings to differential expression analysis and biomarker
discovery in complex cellular extracts, three indepen-
dent iTRAQ experiments with E2 and Tam treated
MCF-7 cells were performed. One 4-plex (involving
four cell culturing conditions) and one double 2-plex
experiment (involving two experimental replicates of
two cell culturing conditions) were conducted for opti-
mization work, and a second double 2-plex experiment
was conducted for the final differential protein expres-
sion analysis. Global correction factors and standard
protein spike iTRAQ ratios, as discussed earlier, are
provided in Table 3/rows 4 to 7, and Table 4/columns
3 and 4, respectively. The double 2-plex experiment was
performed with MCF-7 cells grown in the presence of
E2 (at physiological levels of 1 nM) as a control, and E2
(10 pM)  Tam (at lethal levels of 1 M) as a treatment.
The concentration of E2 in the Tam treated sample was
maintained below levels that can counteract the Tam
effect, i.e., at 10 pM. Two experimental replicates of
each cell state were processed and labeled separately
[E2 (1 nM) treated cells were labeled with reagents 114
and 115, and E2 (10 pM)/Tam (1 M) treated cells were
labeled with reagents 116 and 117], mixed, cleaned-up,
and analyzed by five consecutive LC-MS/MS runs. A
36% increment in the number of identified proteins was
observed when combining the results from the first two
consecutive runs, and a 13% increment was observed
after adding results from a third and fourth injection.
After the fifth injection, the increment in the number of
protein I.D.s was only 8%, thus, further injections
were not performed. A total of 407 proteins (P  0.001)
were identified in the five combined LC-MS/MS runs
when the peptides were filtered with the Xcorr versus
charge state filter set at 1.9, 2.2, and 3.8 for z  1, 2, and
3, respectively. The global correction factors ranged
from 1.44 to 2.23 (Table 3/row 6), and the normalized
iTRAQ values for the 9 proteins spiked into each batch
of cells ranged from 0.52 to 2.16 (Table 4/column 4).
Initially, for all datasets, all proteins with P  0.001
that were matched by peptides that passed the Xcorr
versus charge state filter (1.9, 2.2, 3.8) were considered
for analysis. Using such conditions, the false positive
protein identification rate was 4%. However, when
only proteins matched by two peptides were consid-
ered, as typically required for confident protein identi-
fication, the false positive rate dropped to zero. As a
result, for the E2/Tam treated samples, somewhat less
stringent data filtering parameters were chosen, i.e., the
Xcorr versus charge state peptide filter was set to 1.5,2.0, and 3.0 for singly, doubly, and triply charged ions,
respectively. A total of 530 proteins (P  0.001) were
identified, of which 302 proteins were matched by two
peptides (spectral counts) with a false positive identifi-
cation rate similar to the previous case, i.e., 4%. The
list of 302 proteins was identified by a total of 4074
tandem mass spectra (2648 with P  0.001) correspond-
ing to 1388 unique peptides (732 with P  0.001). To
improve overall quantitation accuracy, the list of 302
proteins was further refined according to the following
criteria (Figure 4): (1) As not all peptides generated
iTRAQ ratios, only the proteins that were quantified by
at least two complete sets of peptide iTRAQ measure-
ments were considered for analysis (i.e., two sets of
116/114, 117/114, 116/115, and 117/115 ratios). Multi-
ple iTRAQ measurements on the same peptide were
allowed to improve quantitation accuracy; (2) a prelim-
inary global normalization was performed to obtain an
estimate of peptide/protein iTRAQ ratios; (3) proteins
that were quantified by only two sets of peptide iTRAQ
measurements that were clearly contradictory after
preliminary normalization (e.g., one showing up-
regulation and the other down-regulation at a larger
than 2-fold level), were eliminated from the list; (4) for
proteins quantified by multiple sets of iTRAQ measure-
ments on the same peptide, tandem mass spectra thatFigure 4. iTRAQ experimental and data processing outline.
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and the protein average iTRAQ values were manually
re-calculated (e.g., when a 5-fold difference between
the value of the iTRAQ ratio for one peptide versus
other peptides with the same amino acid sequence was
observed); (5) proteins for which the two control sam-
ples (E2 treated cells) displayed after global normaliza-
tion a greater than 2-fold change one versus the other
(i.e., 115/114 or 114/115 ratios were 0.5 or 2) were
eliminated from the list; and (6) the final global correc-
tion factors for normalization were recalculated. These
additional data filtering criteria resulted, ultimately, in
a list of 255 proteins (93% being quantified by 3 sets
of iTRAQ measurements). We note that, overall, there
was no significant change in the value of the global
correction factors when less stringent criteria were used
for peptide filtering according to Xcorr versus charge
state, and when the proteins were selected according to
the above described strategy (Table 3, row 7 versus row 6).
After global normalization, the global iTRAQ ratios
matched the theoretical values, i.e., (1:1):(1:1). However,
individual protein iTRAQ ratios continued to display,
occasionally, either a relatively broad range of values,
or conflicting results (e.g., some proteins displayed
up/down-regulation when ion 114, but not ion 115, was
used as a reference, or vice versa). As a result, the set of
255 proteins was subjected to a more advanced statisti-
cal evaluation. The two treatment datasets correspond-
ing to the E2/Tam treated cells (labeled with reagents
116 and 117) were quantified relative to both control
datasets corresponding to the E2 treated cells (labeled
with reagents 114 and 115). Thus, 4 sets of iTRAQ ratios
were generated for each protein: 116/114, 116/115,
117/114 and 117/115. The standard deviations of each
iTRAQ dataset were as follows: (a) for ion 114 consid-
ered as a reference, SD114/114  0, SD115/114  0.31,
SD116/114 0.38 and SD117/114 0.43; and (b) for ion 115
considered as a reference, SD114/115  0.29, SD115/115 
0, SD116/115  0.47 and SD117/115  0.53. The standard
deviations of the two control sets (SD115/114  0.31 and
SD114/115  0.29) were obviously of smaller value and
defined the intrinsic spread of the iTRAQ measure-
ments characteristic to this sample processing protocol
and ion trap PQD technology. We note that the iTRAQ
ratios 114/115 and 115/114—as calculated by the Bio-
works software—did not always represent the recipro-
cal of one another. The standard deviations of the four
treatment sets were of larger value (0.38  SD  0.53),
as a result of protein expression ratio alterations due to
the Tam treatment. To produce consistent threshold
values for outlier identification, the datasets were sub-
jected to quantile normalization [49], performed sepa-
rately for the control and the treatment data, to generate
sets not only having the same mean, but having the
same distribution. The two controls (114/115 and 115/
114) generated an SD  0.3, and the four treatments
(116/114, 117/114, 116/115, and 117/115) an SD 0.45.
Based on the SD of the control, roughly, proteins with a
2-fold change in expression level (beyond 1 3 SD;SD 0.3) would qualify as outliers. As a result, the data
were further evaluated on a log2 scale. Overall, for each
protein, four sets of the following quantities were
calculated: quantile normalized iTRAQ ratio (iTRAQPRONq),
log2(iTRAQPRONq), Z-score of log2(iTRAQPRONq), P value
and adjusted P value. Within each dataset (116/114,
117/114, 116/115, and 117/115), individual Z scores for
each protein were calculated according to eq 5:
Z [log2(iTRAQPRONq)
MEANlog2iTRAQ(C)] ⁄ SDlog2iTRAQ(C) (5)
where MEANlog2iTRAQ(C) and SDlog2iTRAQ(C) are the
mean and SD of the log2iTRAQ ratios for the quantile
normalized control datasets (SDlog2iTRAQ(C)  0.43).
The goal was to identify those proteins whose rel-
ative abundances (i.e., individual iTRAQ ratios)
change in response to Tam treatment. The value of
MEANlog2iTRAQ(C) was very close to zero, which is the
expected log-ratio value under the null hypothesis of no
change. Corresponding to each Z-score in (5), a P value
was computed (for a two-sided test) as:
P-value 2  [1-CDF (ABS(Z)] (6)
where CDF denotes the cumulative distribution func-
tion of the standard normal distribution and ABS de-
notes the absolute value (we note that these computed
P-values refer to protein quantitation, and are different
from the MS2-related P-values generated by the Bio-
works software for protein identification).
To control for multiple testing within each of the four
treatment experiments (116/114, 117/114, 116/115, and
117/115), we used the Benjamini-Hochberg method [50]
for controlling the (expected) false discovery rate (FDR).
From each of the four lists of P values we computed
adjusted P values. The adjusted P value of a protein is
the level at which the FDR would be controlled if that
protein and all other proteins with smaller P values
would be considered as having significant changes in
relative abundance. For example, if the P value corre-
sponding to the Z-score of a protein was 0.001 and the
adjusted P value was 0.018, then calling significant the
relative abundance change for this protein (and any
other protein with P value  0.001) means that the FDR
is controlled at level 0.018 (i.e., 1.8%). Note that the
adjusted P value is always equal to or larger than the
(original) P value because it accounts for multiple
testing. Providing adjusted P values, as in Table 5, is
more informative than only providing the information
whether a certain protein is significant at a pre-chosen
FDR level (say 0.05 or 5%) or not significant. For
example, if the FDR level was prespecified at the 0.05
level, then a protein with adjusted P value of 0.066 and
a protein with adjusted P value of 0.812 would both be
considered as having no significant change in relative
abundance, although the first protein clearly has some
evidence supporting a change in abundance.
Table 5. Differentially expressed proteins in the E2/Tam double 2-plex experiment (ordered in decreasing value of 10xlgP, P being the MS2-related P values). Conditions: MCF-7 cells
were grown in the presence of E2/Tam using the following conditions: (A) E2 (1 nM) and (C) E2 (10 pM)/Tam (1 M). Cell condition A was labeled with reagents 114 and 115, and cell
condition C was labeled with reagents 116 and 117. The samples were mixed in a ratio (A:A):(C:C) of (1:1):(1:1). Peptides were filtered with the Xcorr versus charge state filter set at 1.5,
2.0, and 3.0, and only proteins with P  0.001 and matched by two peptide iTRAQ measurements were counted (see additional selection criteria in the text).
SwissProt
i.d. Protein
10xlgP
(MS2) MW
Peptide Hits/
Unique
iTRAQ
sets
Log2 (iTRAQPRONq)/adjusted P value
#116/114 117/114 116/115 117/115
Q15365
UP
Poly(rC)-binding protein 1; nucleic acid binding, accelerator
of mRNA metabolic processes*
115 37474 8/2 5 1.18
0.066212
1.18
0.066212
1.08
0.106215
0.91
0.199833
0
P30041
DOWN
Peroxiredoxin-6 (antioxidant protein2); response to oxidative
stress
113 24888 10/5 5 2.16
6.70E-05
1.90
0.00063
2.05
0.000153
1.65
0.003526
4
P31930
DOWN
Ubiquinol-cytochrome-c reductase complex core protein I;
respiration, oxidative, reduction, and phosphorylation,
electron transport
111 52612 12/4 8 1.08
0.106215
1.28
0.041074
1.26
0.045644
1.43
0.017745
3
P08195
DOWN
4F2hc cell-surface antigen heavy chain (CD98 antigen);
amino acid transporter, neoplastic cell growth*
103 57909 9/3 2 1.31
0.035208
1.56
0.00753
1.90
0.00063
1.74
0.00196
4
Q5RI18
DOWN
Heterogeneous nuclear ribonucleoprotein U; nucleic acid
binding, RNA metabolism
93 27387 5/2 3 0.99
0.14474
2.16
6.70E-05
1.11
0.094267
2.16
6.70E-05
2
Q15181
DOWN
Inorganic pyrophosphatase; phosphate metabolic processes 91 32639 5/2 5 1.90
0.00063
2.05
0.000153
1.74
0.00196
1.90
0.00063
4
Q6ZUD8
DOWN
CDNA FLJ43793 fis, clone TESTI4000014 (LRP130);
RNA metabolism
86 157862 5/2 2 1.13
0.084941
1.00
0.142992
1.79
0.001306
1.51
0.010281
2
P50454
DOWN
Serpin H1 precursor (collagen-binding protein) (47 kDa
HSP); proliferation-inducing gene 14
80 46411 17/7 12 1.34
0.030601
1.24
0.049065
1.16
0.073528
1.18
0.066212
2
P13693
DOWN
Translationally-controlled tumor protein (p23) (Fortilin); Ca
binding/transport, anti-apoptotic
80 19583 4/2 2 1.51
0.010281
1.46
0.014054
1.86
0.000773
1.86
0.000773
4
P05455
DOWN
Lupus La protein (La autoantigen); mRNA/tRNA binding,
metabolic processes
69 46808 4/2 3 1.79
0.001306
1.74
0.00196
1.56
0.00753
1.56
0.00753
4
O95817
UP
BAG-3 molecular chaperone regulator (BCL-2-binding);
Anti-apoptotic
67 61557 8/4 4 1.69
0.002665
1.21
0.057909
1.69
0.002665
1.69
0.002665
3
Q96QV6
DOWN
Histone H2A type 1-A; transcription, DNA replication, repair,
chromosomal stability*
59 14094 6/2 3 1.74
0.00196
1.43
0.017745
1.34
0.030601
1.24
0.049065
4
P49588
DOWN
Alanyl-tRNA synthetase, (renal carcinoma antigen NY-REN-
42); tRNA binding/processing
52 106743 5/3 4 2.05
0.000153
1.86
0.000773
1.24
0.049065
1.06
0.119007
3
Q99729
DOWN
Heterogeneous nuclear ribonucleoprotein A/B(ABBP1); RNA
metabolism/processing
49 36590 8/4 4 1.46
0.014054
1.51
0.010281
1.51
0.010281
1.37
0.025312
4
Q16695
DOWN
Histone H3.1t; transcription regulation, DNA replication and
repair, chromosomal stability*
42 15367 12/4 10 1.24
0.049065
0.99
0.14474
1.00
0.142992
0.79
0.298926
1
Q96Q06
DOWN
KIAA1881 protein (fragment);
triacylglycerol packaging into adipocytes
30 132978 3/3 3 2.45
3.26E-06
1.34
0.030601
1.65
0.003526
0.86
0.232871
3
P01966 Hemoglobin -bovine (standard) 163 15044 68/8 40 0.73 0.85 0.23 0.24 0
0.350996 0.243858 0.829882 0.822678
P12763 -2HS-glycoprotein–bovine (standard) 110 38394 62/7 37 0.93 0.91 0.62 0.76 0
0.185702 0.199833 0.459976 0.318928
P00921 Carbonic anhydrase 2–bovine (standard) 110 28965 64/13 28 0.32 0.01 0.16 0.18 0
0.755072 0.988855 0.877253 0.863449
P02070 Hemoglobin -bovine (standard) 95 15944 65/9 23 0.14 0.21 0.11 0.01 0
0.891243 0.849519 0.909453 0.988855
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had to qualify as outliers in all four datasets accord-
ing to the following two criteria: (1) at least three out
of four iTRAQ ratios, and (2) the average of all 4
iTRAQ ratios, had to display a minimum of 2-fold
change in relative expression levels on the log2 scale,
i.e., log2(iTRAQPRONq)  |1| (positive values for the
log2 ratios corresponding to up-regulated proteins, neg-
ative values for down-regulated proteins, and zero for
no change in relative expression level). This corre-
sponded to average Z-scores |2.5|. A scatter plot of
the average Z-scores for the 255 protein set, identified in
the E2/Tam treated cells, is provided in the Supplemen-
tal material. Table 5 provides a list of the selected
putative biomarkers with corresponding MS2-related
P-values, molecular weight (MW), total peptide hits/
unique peptides, number of quantifying iTRAQ sets/
protein, set of four log2(iTRAQPRONq) and correspond-
ing adjusted P values for each protein, and the number
of datasets (out of a maximum of four) in which the
protein had an adjusted P value of 0.05 or less. A total
of two proteins were found to be up-regulated and 14
down-regulated. For example, BAG-3 molecular chap-
erone (O95817) was identified by eight peptide hits
(tandem mass spectra), four unique peptides, and quan-
tified by four peptide iTRAQ sets that were averaged
into one final protein iTRAQ set (116/114, 117/114,
116/115, and 117/115). The log2 values of this final set
and the corresponding adjusted P values are listed in
the next columns. All four log2 values were 1, show-
ing a larger than 2-fold up-regulation of this protein,
and three out of the four adjusted P values were0.005,
controlling the FDR at 0.5%. One of the adjusted P
values was 0.057909, equivalent to an FDR 5.8%,
thus exceeding only marginally the typical threshold
of 5%. For the other up-regulated protein, Poly(rC)-
binding protein (Q15365), the adjusted P values indi-
cated control of the FDR at 6.6%, 6.6%, 10.6%, and
19.9%, respectively. A tandem mass spectrum of a
relevant peptide belonging to Poly(rC)-binding protein
1 is provided in the Supplemental material. Again, if a
5% FDR threshold would have been a prespecified
requirement, this protein would not have qualified as
showing a significant change in abundance. In addition,
we note that for the standard bovine protein spikes
shown in Table 5, none of the log2(iTRAQPRONq) and
adjusted P values would have justified the selection of
these standards as up/down regulated candidates, con-
firming, thus, the utility of our statistical approach.
Biological Relevance of Differentially
Expressed Proteins
The estrogen positive MCF-7 cell line is commonly used
in studies that target the elucidation of estrogen/
anti-estrogen modulation of breast cancer development.
The proliferation of estrogen receptor (ER) breast
cancer cells is stimulated by the binding of estrogen/Ta S
w
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ER, that act as ligand-activated transcription factors
[51–55]. The physiological level of 17-estradiol is 1
nM, E2 being the most abundant circulating estrogen in
humans [55]. Tamoxifen, a nonsteroidal compound, is
commonly prescribed in hormonal breast cancer therapy.
Competitive binding of Tam to ERs inhibits estrogen-
mediated events (gene transcription, DNA synthesis,
etc.) that lead to cell proliferation and tumor growth.
Studies have shown that the effect of Tam on breast
cancer cells is mediated through apoptosis [54]. The fine
mechanisms that are at play, however, in E2 stimulation/
Tam inhibition of cell proliferation are not known.
The entire list of 255 quantified proteins was sub-
jected to biological categorization based on information
extracted from the Gene Ontology (GO) database. A
total of 149 proteins returned biological process related
GO assignments, the major categories including pro-
cesses related to mRNA/tRNA processing, transcription/
translation, signaling, metabolic processes, nucleosome/
spliceosome assembly, apoptosis, and protein binding/
folding. Protein differential expression in this study is
expected to occur for the following reasons: (a) as a
direct result of Tam effect on the expression level of
certain proteins; (b) as a result of cell response to stress
inducing conditions; (c) as a result of cell accumulation
in the G1 phase of the cell cycle (it has been shown that
Tam treatment will arrest the cell cycle in the G1 phase)
[56]; or, (d) as a result of changes in post-translational
modifications (PTMs). The proteins that were found to
be up- or down-regulated in the Tam treated cells are all
involved in biological processes that are consistent with
the sources that can induce changes in their expression
level (Table 5). For example, the finding that BAG3 was
up-regulated in Tam treated cells is very interesting, as
it was recently shown that BAG3 has anti-apoptotic
activity, and that expression of BAG3 in neoplastic cells
sustains cell survival in response to stress inducing
factors. It is also believed that BAG3 could be respon-
sible for impairing response to therapy, and could
represent a novel therapeutic target [57]. The other
up-regulated protein, Poly(rC)-binding protein 1, is a
nucleic acid binding protein that functions as an accel-
erator of mRNA metabolic processes and has roles in
mRNA stabilization, translational activation and trans-
lational silencing [58, 59]. In addition, several proteins
with role in cell proliferation and tumorigenesis that are
up-regulated in cancerous cell states have been found to
be down-regulated in the Tam treated cells. The prelim-
inary double 2-plex experiment that returned 154 quan-
tified proteins, and the 4-plex experiment that returned
145 proteins, enabled the confirmation of up/down
regulation for four proteins from Table 5 according to
most of the stringency parameters imposed in our study
(see proteins marked with an asterisk). The other pro-
teins in the list could not be confirmed, either as a result
of the protein not being identified/quantified in the
smaller datasets, or as a result of the protein not passing
the quality criteria imposed for accurate quantitation.While the E2/Tam cultured cells served only as a model
system for evaluating the effectiveness of the PQD
linear ion trap technology and of our newly developed
method for identifying differentially expressed pro-
teins, the present findings seem very promising, and
additional studies involving the use of complementary
techniques, such as Western blotting and MS multiple
reaction monitoring, will be conducted on biological
replicates to confirm the differential expression of these
proteins.
Conclusions
In this work, a one-step LC-MS/MS approach, using
iTRAQ/PQD ion trap MS technology, has been devel-
oped to perform differential expression profiling of
complex proteomic cellular extracts. The effectiveness
of the method was evaluated on MCF-7 breast cancer
cells cultured in the presence of E2 and Tam. The
detection of protein up/down regulation at a 2-fold
threshold change in expression level was enabled by the
development of: (1) a data dependent MS acquisition
strategy that involved the analysis of two experimental
replicates of two cell states (double 2-plex), (2) an
advance data filtering strategy that involved multiple
decisions at the peptide and protein level, and (3) a
statistical data validation strategy that involved global/
quantile normalization, log2 transformation, Z-score
generation and adjusted P value calculation for control-
ling the FDR. Ultimately, the method enabled the
detection/quantitation of 530/255 proteins (P  0.001),
and the selection of 16 differentially expressed proteins,
demonstrating the potential of iTRAQ/PQD-MS for
biomarker discovery applications. Most importantly, it
was determined that these proteins are implicated in
cancer-relevant biological processes such as cell prolif-
eration, apoptosis, oncogenesis and metastasis. The
corroborated change in expression level of these pro-
teins in Tam treated cells has not been reported, so far,
thus, the biological significance of this outcome requires
further validation. It is anticipated that a proper assess-
ment of protein up/down regulation in the larger
context of biochemical signaling pathways will have a
significant impact on elucidating the molecular mecha-
nisms that control Tam inhibition of cell proliferation
and cell response to stress inducing conditions. Ulti-
mately, a better understanding of how breast tumor
cells develop Tam resistance will lead to the identifica-
tion of novel therapeutic targets and more effective
treatment options for cancer patients.
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